Immunogenicity and Safety of AdCLD-CoV19-1 OMI as a Booster: A COVID-19 Preventive Vaccine in Healthy Volunteers

COVID-19 Clinical Trial

— COVID-19  

Official title:

A Phase III Multinational, Multicenter, Observer-Blinded, Randomized, Active-Controlled Trial to Evaluate the Immunogenicity and Safety of the Preventive COVID-19 Vaccine AdCLD-CoV19-1 OMI Administered as a Booster to Adults Aged 19 Years Old and Above

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05993325
• Other study ID #: COVENT-202
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: September 2023
• Est. completion date: May 2025

Study information

• Verified date: August 2023
• Source: Cellid Co., Ltd.
• Contact: Wuhyun Kim, D.V.M
• Email: whkim[@]cellid.co.kr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The immunogenicity and safety of AdCLD-CoV19-1 OMI (5.0x10^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old and above will be evaluated. Outcome assessment will be performed in comparison with Comirnaty Bivalent.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 4000
• Est. completion date: May 2025
• Est. primary completion date: May 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Individual aged 19 and above and willing to provide written informed consent to participate study voluntarily.

2. Individual fall under one or more of the following at the date of IP administration

• At least past 16 weeks (112 days) without additional COVID-19 vaccination since the last COVID-19 vaccination.

• At least past 16 weeks (112 days) since the release of quarantine due to COVID-19 confirmation.

3. Individual who agrees to use medically acceptable contraceptive methods† for at least 4 weeks prior to screening and 12 weeks post IP administration.

4. Individual who agrees not to donate or transfuse blood (including whole blood, plasma components, platelet components, platelet plasma components) throughout the study participation.

Exclusion Criteria:

1. Individual fall under one or more of the following at the date of IP administration

• History of COVID-19 within 16 weeks (-111~0 days) or considered to be infected prior to IP administration.

• History of receiving COVID-19 vaccine within 16 weeks (-111~0 days) prior to IP administration.

2. Clinically significant abnormalities on clinical laboratory tests, electrocardiograms, and chest X-rays performed during screening visit.

3. Positive HIV test result on the screening test.

4. Acute febrile illness with (=38°C), or any suspected infectious diseases, or COVID-19-like symptoms (cough, shortness of breath, chills, myalgia, headache, sore throat, loss of taste/smell, etc.) within 3 days prior to administration of IP.

5. Any serious medical or psychiatric disease which in opinion of investigator judges unable to participate.

• Respiratory diseases: Asthma, Chronic Obstructive Pulmonary Disease (COPD), active or latent tuberculosis which require medication, or individual who has received treatment due to worsening of the listed respiratory disease within 5 years prior to administration of IP.

• Serious cardiovascular diseases: Congestive heart failure, coronary artery disease, myocardial infarction, uncontrolled hypertension, thrombocytopenia or venous thrombosis, capillary leakage syndrome, myocarditis, pericarditis, etc.

• Neurologic diseases: Epilepsy, seizure within past 3 years, migraine, stroke, encephalopathy, Guillain-Barre Syndrome, encephalomyelitis, transverse myelitis, etc.

• Malignant cancer diagnosed within past 5 years (skin basal cell and squamous cell carcinoma are excluded).

• Immune function disorders including autoimmune hypothyroidism, psoriasis.

• Immunodeficiency diseases.

• History of dependently administering psychotropic drugs or narcotic analgesics within 24 weeks prior to administration of IP, or psychiatric disease or behavioral impairment that, in the opinion of the investigator, could interfere with the participant's ability to participate in the study.

• Other hepatobiliary, renal, endocrine, urinary tract, muscular skeletal diseases which the investigator considers clinically significant.

6. History of splenectomy.

7. Known history of allergic or hypersensitivity to the components of IP.

8. Known history of serious adverse reaction, allergies or hypersensitivity related to vaccination.

9. Individual with history of bleeding diathesis or thrombocytopenia, or history of severe bleeding or bruising after intramuscular injection or venipuncture or is receiving an anticoagulant (Individual receiving low dose aspirin (less than 100mg/day) can be enrolled in judgement of investigator).

10. History of hereditary or idiopathic angioneurotic edema.

11. History of systemic urticaria within 5 years prior to administration of IP.

12. Individual with history of solid organ or bone marrow transplantation.

13. Individual who is suspected or with history of drug or alcohol abuse within 24 weeks prior to administration of IP.

14. History of licensed drug for COVID-19 prevention aside from COVID-19 vaccine within 52 weeks prior to administration of IP.

15. Use of immunosuppressive or chronic use of systemic steroids within 6 weeks prior to administration of IP (Topical steroids, nasal spray and inhalers are allowed).

• Immunosuppressive: Azathioprine, Cyclosporine, Interferon, G-CSF, Tacrolimus, Everolimus, Sirolimus, Cyclophosphamide, 6-Mercaptopurine, Methotrexate, Rapamycin, Leflunomide, etc.

• Chronic steroid: >10 mg/day prednisone equivalent for periods exceeding 14 days.

16. Individual who has administered other investigational product or device within 24 weeks prior to screening visit.

17. Individual who has received or planned to receive any other vaccines within 28 days prior and after the administration of IP (Flu vaccines can be administered up to 14 days prior to the date of IP administration).

18. Receipt of immunoglobulin or blood-derived products within 12 weeks prior to administration of IP.

19. Individual with scheduled surgery throughout the study period.

20. Pregnant or lactating women.

21. Individual directly related to the investigator and meets the following:

• Personnel relationship or subordinate-superior relationship (employees of the investigator's department, staffs of this trial).

• Students or researchers in the immediate department of the school to which the investigator belongs (e.g., medical university).

22. Individual who is unfit for this study for any other reason in judgement of investigator.

Related Conditions & MeSH terms

• COVID-19
• Vaccines

Intervention

Biological:
• AdCLD-CoV19-1 OMI
3000 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular administration in the deltoid muscle
• Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)
1000 participants will receive investigational product (Comirnaty Bivalent) via intramuscular administration in the deltoid muscle

Locations

Country	Name	City	State
Korea, Republic of	Dong-a University Hospital	Busan
Korea, Republic of	Kyungpook National University Hospital	Daegu
Korea, Republic of	Chungnam National University Hospital	Daejeon
Korea, Republic of	Chonnam National University Hospital	Gwangju
Korea, Republic of	Hallym University Dongtan Sacred Heart Hospital	Gyeonggi-do
Korea, Republic of	Korea University Ansan Hospital	Gyeonggi-do
Korea, Republic of	The Catholic University of Korea, ST. Vincent's Hospital	Gyeonggi-do
Korea, Republic of	Gachon University Gil Medical Center	Incheon
Korea, Republic of	Inha University Hospital	Incheon
Korea, Republic of	Hallym University Kangnam Sacred Heart Hospital	Seoul
Korea, Republic of	Korea University Guro Hospital	Seoul
Korea, Republic of	Samyook Medical Center	Seoul
Korea, Republic of	The Catholic University of Korea, Eunpyeong St. Mary's Hospital	Seoul
Korea, Republic of	Veterans Health Service Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Cellid Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	SRR, GMT, GMFR of SARS-CoV-2 Wuhan strain and Variants of concern (VOC) neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.		At 28 days post IP administration
Other	SRR, GMT, GMFR of SARS-CoV-2 B.1.1.529 S protein-specific antibody measured by ELISA at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.		At 28 days post IP administration
Other	Cellular immune response (CMI) measured by ELISpot at 28 days, 26, 52 weeks post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.	Cellular immune response (CMI: responder rate, spot-forming unit) measured by ELISpot at 28 days, 26, 52 weeks post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.	At 28 days, 26, 52 weeks post IP administration.
Other	Differences of SRR, GMT, GMFR of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration by previous COVID-19 vaccination series.		At 28 days post IP administration
Other	Differences of SRR, GMT, GMFR of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration by age.		At 28 days post IP administration
Other	Proportion of COVID-19 cases confirmed by antigen test from 14 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration to the end of the study.		Throughout the study duration, 12 months post IP administration
Other	Proportion of severe COVID-19 cases from 14 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration to the end of the study.		Throughout the study duration, 12 months post IP administration
Other	Proportion of hospitalization due to COVID-19 cases from 14 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration to the end of the study.		Throughout the study duration, 12 months post IP administration
Other	Proportion of mortality due to COVID-19 cases from 14 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration to the end of the study.		Throughout the study duration, 12 months post IP administration
Primary	Ratio of GMT of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration	Ratio of GMT of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration (GMT of AdCLD-CoV19-1 OMI / GMT of Comirnaty Bivalent).; Geometric mean titer (GMT): The value of multiplying the antibody titer of all available subjects (N) and take the Nth order root value.	At 28 days post IP administration
Primary	Difference in seroresponse rate (SRR) of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration	Difference in seroresponse rate (SRR) of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration (SRR of AdCLD-CoV19-1 OMI - SRR of Comirnaty Bivalent).; Seroresponse rate (SRR): Proportion of subjects whose antibody titer rise at least 4-fold at the measurement point compared to baseline. The titer is defined as half of detection limit if the titer before administration is below detection limit.	At 28 days post IP administration
Secondary	SRR (proportion of subject who achieved seroresponse), GMT, GMFR of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 26, 52 weeks post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.	SRR (proportion of subject who achieved seroresponse), GMT (Geometric mean titer), GMFR (Ratio of GMT or GMC rise at the measurement point compared to baseline) of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 26, 52 weeks post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.	At 26, 52 weeks post IP administration
Secondary	Differences in SRR, GMT, GMFR of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration by serostatus of SARS-CoV-2 N protein antibody.	Differences in seroresponse rate (SRR), geometric mean titer (GMT), geometric mean fold rise (GMFR) of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration by serostatus of SARS-CoV-2 N protein antibody.	At 28 days post IP administration
Secondary	Differences in SRR, GMT, GMFR of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration by country.	Differences in seroresponse rate (SRR), geometric mean titer (GMT), geometric mean fold rise (GMFR) of SARS-CoV-2 B.1.1.529 neutralizing antibody measured by wild-type virus neutralization assay at 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration by country.	At 28 days post IP administration
Secondary	Proportion of immediate adverse events (AE)	Immediate adverse events occurred within 30 minutes (2 hours for =75 years old) post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.	Within 30 minutes post IP administraiton
Secondary	Proportion of solicited local and systemic AE	Solicited AEs occurred within 7 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.	Within 7 days (Days 0 - 6) post IP administration
Secondary	Proportion of unsolicited AE	Unsolicited AEs occurred within 28 days post AdCLD-CoV19-1 OMI or Comirnaty Bivalent administration.	Within 28 days (Days 0 - 27) post IP administration
Secondary	Proportion of SAE		Throughout the study duration, 12 months post IP administration
Secondary	Proportion of Adverse Event Of Special Interest (AESI)		Throughout the study duration, 12 months post IP administration
Secondary	Proportion of Medically-Attended Adverse Events (MAAE)		Throughout the study duration, 12 months post IP administration
Secondary	Proportion of clinically significant changes in clinical laboratory tests		At 28 days post IP administration
Secondary	Proportion of clinically significant changes in vital signs		At 28 days post IP administration
Secondary	Proportion of clinically significant changes in physical examination		At 28 days post IP administration